Merck Obtains Access To SurModics’ Ophthalmic Drug Delivery System In Potential $300 Million Deal
This article was originally published in The Pink Sheet Daily
I-vation system is currently being studied in combination with triamcinolone acetonide for treatment of diabetic macular edema.
You may also be interested in...
Agreement with Australian firm gives Pfizer access to novel, controlled-release drug delivery technology.
Further development follows the release of a positive Phase II interim analysis of the wet age-related macular degeneration candidate.
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?